Regina Gironés Sarrió

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Chung‐Han Lee, Amishi Y. Shah, Drew Rasco et al. · The Lancet Oncology · 2021 · 186 citations · Full text

Medicine, Oncology, Pharmacology +15

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

Nicolò Matteo Luca Battisti, Anna Rachelle Mislang, Lisa Cooper et al. · Journal of Geriatric Oncology · 2020 · 80 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

Chung‐Han Lee, Amishi Y. Shah, James J. Hsieh et al. · Journal of Clinical Oncology · 2020 · 42 citations

Medicine, Oncology, Pharmacotherapy +17